Pivotal readout
Positive EU Opinion for WELIREG
The EMA's CHMP recommended approval of WELIREG plus lenvatinib for adults with advanced clear cell renal cell carcinoma following PD-1 or PD-L1 inhibitor treatment. The European Commission decision remains pending.
In the Phase 3 LITESPARK-011 trial, the combination reduced the risk of progression or death by 26% versus cabozantinib; final overall survival results did not meet statistical significance. Serious adverse reactions occurred in 54% of combination-treated patients.
Key risks included anemia, hypoxia, cardiac dysfunction and embryo-fetal toxicity.
- Drugbelzutifan
- Druglenvatinib
- TargetHypoxia-inducible factor 2-alpha
- TargetFibroblast growth factor receptor 1
- TrialNCT04586231
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.